The first CD20xCD3 bispecific antibody will soon become available in the US following an FDA approval disclosed Thursday night.
Roche and Genentech’s mosunetuzumab was greenlit as a third-line treatment for adults with relapsed or refractory follicular lymphoma. FDA’s accelerated approval of the therapy now branded as Lunsumio comes seven days...
